4 results match your criteria: "Second Hospital Affiliated to Fujian Medical University[Affiliation]"

Objective: To investigate the correlation of the anterior lobe thickness of the prostate (ALTP) with bladder outlet obstruction (BOO), and evaluate the effect of ALTP on the clinical progression of BPH.

Methods: This retrospective study included 159 cases of BPH. We obtained the clinical indicators of the patients, including ALTP, prostate volume (PV), postvoid residual urine (PVR), maximum urinary flow rate (Qmax), BOO index (BOOI) and IPSS, and analyzed the correlations of ALTP with IPSS, PV, Qmax, age, PVR and BOOI.

View Article and Find Full Text PDF

Background: Numerous abnormally expressed miRs have been reported involved in oxaliplatin (L-OHP) resistance of colorectal cancer (CRC). The present study aimed to investigate whether miR-200b-3p could regulate L-OHP resistance via targeting TUBB3 in CRC cells.

Methods: L-OHP resistant HT29 and HCT116 cells were exposed to escalating concentrations of L-OHP up to 30 μm.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates dyslipidemia prevalence and cardiovascular disease (CVD) risk among older adults in Quanzhou, China, using a survey of 2,018 residents aged 60-98 from September 2016 to March 2018.
  • Findings reveal a high prevalence of dyslipidemia at 56.8%, with specific lipid abnormalities including elevated total cholesterol (TC) and low high-density lipoprotein cholesterol (HDL-C).
  • The majority of participants had moderate (36.8%) or high (13.5%) CVD risk, and factors like age, body mass index, and abdominal obesity were linked to increased LDL cholesterol levels, highlighting the need for targeted prevention strategies for older adults.
View Article and Find Full Text PDF

Purpose: Immunotherapy in the clinic has demonstrated its potential to control cancer through disinhibiting the immune system, especially for immune checkpoint inhibitors such as anti-programmed cell death protein 1/anti-programmed death-ligand 1 (anti-PD1/anti-PD-L1). However, although these new immunotherapies have resulted in durable clinical responses in various cancers, multiple mechanisms of immune resistance and suppression exist in tumors. One significant barrier to efficacy of anti-PD1 against colon cancer may be the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment.

View Article and Find Full Text PDF